Target intelligence / Profile preview

Bungarus caeruleus venom toxins

Molecular classification
Neurotoxin, Phospholipase A2, Three-finger toxin, Enzyme, Other
01

Overview

Bungarus caeruleus venom toxins are a complex mixture of proteins and peptides secreted by the Common Krait, a highly venomous elapid snake native to South Asia (WHO, 2021). The primary constituents are neurotoxins, including presynaptic beta-bungarotoxins with phospholipase A2 activity and postsynaptic three-finger toxins (UniProt, 2023). These toxins collectively disrupt neuromuscular transmission, leading to progressive muscle paralysis and potentially fatal respiratory failure (StatPearls, 2023). While not therapeutic targets in the traditional sense, they are the pathological targets for neutralization by polyvalent antivenoms (PubMed, 2022). Understanding these toxins is critical for managing envenomation, which often presents with minimal local symptoms but rapid systemic neurotoxicity (NIH, 2020). The presynaptic toxins are particularly dangerous as they cause irreversible damage to nerve terminals, making early treatment vital.

Other names
Common Krait venomBungarus caeruleus neurotoxinsKrait venom toxins
02

Mechanism of action

Antivenom antibodies bind to the venom proteins (toxins), forming complexes that are cleared from the circulation, thereby preventing the toxins from reaching their physiological targets like the nicotinic acetylcholine receptor or presynaptic membranes (StatPearls, 2023). Neostigmine acts as an acetylcholinesterase inhibitor to temporarily increase acetylcholine concentration at the neuromuscular junction, although its efficacy is limited against Krait venom due to the presynaptic nature of the toxins (PubMed, 2021).

03

Biological functions

Inhibition of neurotransmitter releaseNicotinic acetylcholine receptor antagonismPhospholipid degradationOther
04

Disease associations

Snakebite envenomationNeuromuscular paralysisRespiratory failureOther
05

Safety considerations

Antivenom-induced anaphylaxisSerum sicknessIrreversible presynaptic damage
06

Interacting drugs

Snake venom antiserum (polyvalent)

2 more in the full profile.

07

Biomarkers

Venom antigen detection (ELISA)Whole blood clotting time (WBCT)Serum creatine kinase

Beyond the preview

Go deeper on Bungarus caeruleus venom toxins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bungarus caeruleus venom toxins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call